lunes, 14 de abril de 2014

Tumor Markers

full-text ►

Tumor Markers

Clinical Policy Bulletin:
Tumor Markers

Number: 0352


  1. Aetna considers any of the following serum tumor markers for the stated indication medically necessary:

    1. Prostate-specific antigen (PSA) for prostate cancer screening (see CPB 0521 - Prostate Cancer Screening), staging, monitoring response to therapy, and detecting disease recurrence. 
    2. Carcinoembryonic antigen (CEA) for any of the following:

      1. As a preoperative prognostic indicator in members with known colorectal carcinoma or mucinous appendiceal carcinoma when it will assist in staging and surgical treatment planning; or 
      2. To detect asymptomatic recurrence of colorectal cancer after surgical and/or medical treatment for the diagnosis of colorectal cancer (not as a screening test for colorectal cancer); or
      3. To monitor response to treatment for metastatic cancer.

No hay comentarios:

Publicar un comentario